Form 4: Kymera Director Sells Shares Under 10b5-1 Plan

Kymera Therapeutics Director Bruce Booth reported the sale of 231,588 shares of common stock over three days in December 2025, executed under a Rule 10b5-1 trading plan.

Summary

• Bruce Booth, a Director of Kymera Therapeutics, Inc., reported the sale of 231,588 shares of common stock.
• The sales occurred on December 10, 2025, December 11, 2025, and December 12, 2025.
• The transactions were executed pursuant to a Rule 10b5-1(c) trading plan, indicating they were pre-scheduled.
• Shares were sold at weighted average prices ranging from $88.64 to $93.20.
• The total value of the shares sold is approximately $21,700,400.16.
• Following these transactions, the beneficial ownership held indirectly by Atlas Venture Fund X, L.P. was 3,974,481 shares, and by Atlas Venture Opportunity Fund I, L.P. was 685,393 shares.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While significant insider selling can be a negative signal, the fact that these transactions were conducted under a Rule 10b5-1 plan mitigates much of the potential negative interpretation, as they were pre-scheduled and not indicative of new, adverse information.

Positives

• The sales were conducted under a pre-arranged Rule 10b5-1 trading plan, which suggests the transactions were scheduled in advance and not based on new, non-public information, thereby mitigating the typical negative signal of insider selling.

Negatives

• A significant volume of insider selling, totaling 231,588 shares, reduces the overall insider ownership stake in the company.
• Despite being pre-planned, large insider sales can sometimes be perceived negatively by the market, potentially leading to a cautious sentiment among investors.

Risks

• The reduction in insider ownership, even if pre-planned, could be interpreted by some investors as a decrease in management's direct financial alignment with shareholder interests.
• While mitigated by the 10b5-1 plan, any significant insider selling carries the inherent risk of negatively influencing investor sentiment and potentially the stock price.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Industry Context

This insider transaction report does not provide specific details that allow for a direct analysis of broader industry trends or competitor performance. It primarily reflects an individual director's pre-planned stock sales.

Related Party Transactions

• Bruce Booth, a Director, reported sales of common stock held indirectly through Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P. He is a member of the general partners of these funds and disclaims Section 16 beneficial ownership except for his pecuniary interest, which is a standard disclosure for fund managers.

Stakeholder Impact

• Shareholders may view the significant insider selling, even if pre-planned, with some caution, as it reduces the overall insider ownership stake.
• The disclosure of sales under a Rule 10b5-1 plan helps mitigate potential negative perceptions by indicating the transactions were scheduled in advance and not based on new, non-public information, which can reassure investors about the transparency of the sales.

Key Dates

Recommendation

The director's sale of a significant number of shares, while notable, was conducted under a pre-arranged Rule 10b5-1 trading plan. This suggests the transactions were scheduled in advance and not driven by new, material non-public information, thereby neutralizing much of the typical negative sentiment associated with insider selling. Without additional context on the company's performance or strategic direction, these routine sales do not provide a strong basis for a 'buy' or 'sell' recommendation, thus a 'hold' stance is appropriate.

Keywords

Kymera Therapeutics, KYMR, Bruce Booth, Insider Trading, Form 4, Stock Sale, 10b5-1 Plan, Director, Beneficial Ownership, Atlas Venture